These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15142482)

  • 1. The Use of Ketolides in Treatment of Upper Respiratory Tract Infections.
    Zhanel GG; Wierzbowski AK; Hisanaga P; Hoban DJ
    Curr Infect Dis Rep; 2004 Jun; 6(3):191-199. PubMed ID: 15142482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will resistance to ketolides develop in Streptococcus pneumoniae?
    Leclercq R
    J Infect; 2002 Feb; 44 Suppl A():11-6. PubMed ID: 12150490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J
    Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ketolides: a critical review.
    Zhanel GG; Walters M; Noreddin A; Vercaigne LM; Wierzbowski A; Embil JM; Gin AS; Douthwaite S; Hoban DJ
    Drugs; 2002; 62(12):1771-804. PubMed ID: 12149046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of ketolides vs. macrolides.
    Douthwaite S
    Clin Microbiol Infect; 2001; 7 Suppl 3():11-7. PubMed ID: 11523556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telithromycin: an oral ketolide for respiratory infections.
    Bearden DT; Neuhauser MM; Garey KW
    Pharmacotherapy; 2001 Oct; 21(10):1204-22. PubMed ID: 11601667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
    Yassin HM; Dever LL
    Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketolides in the treatment of respiratory infections.
    Zhanel GG; Hoban DJ
    Expert Opin Pharmacother; 2002 Mar; 3(3):277-97. PubMed ID: 11866679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketolides in the treatment of community-acquired respiratory tract infections: A review.
    Lipsky MS
    Curr Ther Res Clin Exp; 2005 May; 66(3):139-53. PubMed ID: 24672119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
    Low DE; Brown S; Felmingham D
    Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.
    Zhanel GG; Hisanaga T; Nichol K; Wierzbowski A; Hoban DJ
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):297-321. PubMed ID: 14661991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telithromycin: the first of the ketolides.
    Shain CS; Amsden GW
    Ann Pharmacother; 2002 Mar; 36(3):452-64. PubMed ID: 11895060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
    Felmingham D; Zhanel G; Hoban D
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of new antibacterial therapies in at-risk populations.
    Lorenz J
    J Infect; 2002 Feb; 44 Suppl A():25-30. PubMed ID: 12150492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
    Carbon C
    Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance].
    Gómez-Garcés JL; Alós JI; Hernáiz C; Gómez C
    Enferm Infecc Microbiol Clin; 2004; 22(6):323-7. PubMed ID: 15228898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.